M. A. Emtsev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
M. A. Emtsev has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Aleksey G. Kotelnikov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
1 shared publication - Alexey L. Shestakov
Department of Hospital Surgery No. 2, Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia
1 shared publication - Andrey M. Nikolaev
Department of Hospital Surgery No. 2, Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia
1 shared publication - Evgeniy A. Tarabrin
Department of Hospital Surgery No. 2, Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia
1 shared publication - Mehrshad Ebrahimnezhad
Cardiology Department No. 2, Yudin City Hospital of Moscow, The Patrice Lumumba Peoples’ Friendship University of Russia (RUDN), 117198 Moscow, Russia
1 shared publication - Milena Yu. Ivanova
Department of Hospital Surgery No. 2, Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia
1 shared publication
Latest Publications
- Open Access
- 28 September 2026
- Published by MDPI AG in Metabolites
- Vol. 16 (10) , 721
Bile Biochemistry as a Therapeutic Target in Biliary Surgery: Disease-Specific Evidence and Clinical Limits
Background/Objectives: Bile acid therapies have expanded treatment options for cholestatic disease, but their relevance to biliary surgery depends on the diagnosis and endpoint. This critical narrative review examines where molecular evidence changes care and where surgical applications remain untested. Methods: The existing synthesis was supplemented by targeted literature searches and regulatory checks completed on 20 September 2026. Studies were assessed by design, population, outcome, and applicability to surgical decisions. Results: Genetic assessment can identify inherited cholestasis or selected recurrent lithogenic disorders that persist after anatomical treatment. Evidence for ileal bile acid transporter inhibitors supports indication-specific relief of cholestatic pruritus. Recent trials of receptor agonists show that biochemical, symptomatic, and disease-progression outcomes can diverge. Observational studies support biliary diversion in selected patients with inherited cholestasis, although comparisons among procedures and with drug treatment remain uncertain. The expanding genetic spectrum of progressive familial intrahepatic cholestasis and real-world treatment reports refine patient selection but provide limited evidence for long-term surgical outcomes. Bile metabolomics and synthesis markers remain unvalidated for timing cholecystectomy. Conclusions: Molecular findings are useful when they answer a defined diagnostic or therapeutic question. They can guide specialist treatment and surveillance alongside anatomical assessment. Prospective studies must establish whether molecular stratification improves outcomes in biliary surgical populations.
- 28 September 2026
- Published by MDPI AG in Metabolites
- Vol. 16 (10) , 721
Open AccessBile Biochemistry as a Therapeutic Target in Biliary Surgery: Disease-Specific Evidence and Clinical Limits
Background/Objectives: Bile acid therapies have expanded treatment options for cholestatic disease, but their relevance to biliary surgery depends on the diagnosis and endpoint. This critical narrative review examines where molecular evidence changes care and where surgical applications remain untested. Methods: The existing synthesis was supplemented by targeted literature searches and regulatory checks completed on 20 September 2026. Studies were assessed by design, population, outcome, and applicability to surgical decisions. Results: Genetic assessment can identify inherited cholestasis or selected recurrent lithogenic disorders that persist after anatomical treatment. Evidence for ileal bile acid transporter inhibitors supports indication-specific relief of cholestatic pruritus. Recent trials of receptor agonists show that biochemical, symptomatic, and disease-progression outcomes can diverge. Observational studies support biliary diversion in selected patients with inherited cholestasis, although comparisons among procedures and with drug treatment remain uncertain. The expanding genetic spectrum of progressive familial intrahepatic cholestasis and real-world treatment reports refine patient selection but provide limited evidence for long-term surgical outcomes. Bile metabolomics and synthesis markers remain unvalidated for timing cholecystectomy. Conclusions: Molecular findings are useful when they answer a defined diagnostic or therapeutic question. They can guide specialist treatment and surveillance alongside anatomical assessment. Prospective studies must establish whether molecular stratification improves outcomes in biliary surgical populations.
- Open Access
- 28 August 2026
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 25 (3) , 136-145
“Textbook outcomes” in colorectal surgery (a systematic review)
OBJECTIVE: to analyze existing definitions of “textbook outcome” (TO) in colorectal cancer surgery and to justify the need for their standardization. P ATIENT S AND METHODS: a systematic review was conducted in accordance with the PRISMA guidelines. PubMed, the Cochrane Library, and eLIBRARY were searched for the period 2010-2025. Original studies evaluating TO in adult patients after surgical treatment for colorectal cancer were included. Study quality was assessed using the Newcastle-Ottawa scale. RESULT S: sixteen studies (335,575 patients) were included. The rate of achieving TO ranged from 28.5% to 77.4%. Significant heterogeneity in TO definitions was identified. The most common components were R0 resection, lymph node dissection ≥ 12, absence of major complications (Clavien-Dindo ≥ III), readmissions, and mortality (30/90 days), as well as length of hospitalization (fixed values or 75th percentile). Achieving TO was associated with improved survival (a 40-55% reduction in the risk of death). Significant factors included surgical approach, ERAS, age, comorbidities, stage, neoadjuvant therapy, insurance type, and surgical volume. CONCLUSION: TO is a valid tool for assessing the quality of surgical treatment of colorectal cancer associated with long-term survival. The lack of a unified definition limits the comparability of results. The proposed standardized definition (R0 resection, lymph node dissection ≥ 12, absence of major complications, 30-day mortality and readmissions, length of stay within the 75th percentile) can serve as the basis for international consensus.
- 28 August 2026
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 25 (3) , 136-145
Open Access“Textbook outcomes” in colorectal surgery (a systematic review)
OBJECTIVE: to analyze existing definitions of “textbook outcome” (TO) in colorectal cancer surgery and to justify the need for their standardization. P ATIENT S AND METHODS: a systematic review was conducted in accordance with the PRISMA guidelines. PubMed, the Cochrane Library, and eLIBRARY were searched for the period 2010-2025. Original studies evaluating TO in adult patients after surgical treatment for colorectal cancer were included. Study quality was assessed using the Newcastle-Ottawa scale. RESULT S: sixteen studies (335,575 patients) were included. The rate of achieving TO ranged from 28.5% to 77.4%. Significant heterogeneity in TO definitions was identified. The most common components were R0 resection, lymph node dissection ≥ 12, absence of major complications (Clavien-Dindo ≥ III), readmissions, and mortality (30/90 days), as well as length of hospitalization (fixed values or 75th percentile). Achieving TO was associated with improved survival (a 40-55% reduction in the risk of death). Significant factors included surgical approach, ERAS, age, comorbidities, stage, neoadjuvant therapy, insurance type, and surgical volume. CONCLUSION: TO is a valid tool for assessing the quality of surgical treatment of colorectal cancer associated with long-term survival. The lack of a unified definition limits the comparability of results. The proposed standardized definition (R0 resection, lymph node dissection ≥ 12, absence of major complications, 30-day mortality and readmissions, length of stay within the 75th percentile) can serve as the basis for international consensus.